New FDA Warning on GLP-1 Receptor Agonists: Pulmonary Aspiration Risk During Anesthesia
The FDA has issued a warning about delayed gastric emptying with GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) that can lead to pulmonary aspiration during general anesthesia or deep sedation, requiring patients to inform healthcare providers of any planned surgeries or procedures. 1
The Core Safety Issue
GLP-1 receptor agonists slow gastric emptying as part of their mechanism of action—this is how they promote satiety and weight loss. However, this delayed gastric emptying persists even when patients are fasting for procedures, potentially leaving residual gastric contents that can be aspirated during intubation or sedation 2, 3.
What the Evidence Shows
- Case reports have documented regurgitation and pulmonary aspiration in patients on GLP-1 RAs undergoing elective procedures 2
- In the elective surgical setting, one study reported an odds ratio of 10.23 (95% CI 2.94-35.82) for pulmonary aspiration risk 2
- In endoscopy settings, a hazard ratio of 1.33 (95% CI 1.02-1.74) was observed 2
- The European Medicines Agency Pharmacovigilance Risk Assessment Committee has highlighted this concern 2
The Uncertainty Around Long-Term Use
A critical caveat: The magnitude of risk in patients on long-term GLP-1 RA therapy remains unclear due to potential tachyphylaxis (tolerance) effects on gastric emptying 2. However, the FDA warning applies regardless of treatment duration, taking a cautious approach given the severity of aspiration complications.
How to Counsel Your Patients
Key Points to Communicate
1. Inform All Healthcare Providers
- Patients must tell their surgeon, anesthesiologist, and proceduralist that they are taking a GLP-1 RA before any planned surgery or procedure requiring anesthesia or deep sedation 1
- This includes both elective surgeries and procedures like colonoscopies or upper endoscopies
2. Medication Timing Before Procedures The American Society of Anesthesiologists initially recommended:
- Daily injections (liraglutide): Stop the day before the procedure
- Weekly injections (semaglutide, tirzepatide, dulaglutide): Stop one week before the procedure 2
However, newer multidisciplinary consensus guidelines suggest more nuanced approaches based on individual risk assessment, as the evidence for optimal timing remains limited 2.
3. The Mechanism Explained Tell patients: "This medication slows down how quickly your stomach empties food. Even when you fast before surgery, there may still be contents in your stomach that could come back up during anesthesia, which is dangerous. Your anesthesia team needs to know so they can take extra precautions."
Other Critical Safety Warnings to Reinforce
While discussing the aspiration risk, reinforce these established warnings:
Thyroid C-Cell Tumors
- GLP-1 RAs caused thyroid tumors in rodents; human relevance unknown 4, 1
- Patients should report neck lumps, hoarseness, difficulty swallowing, or shortness of breath
Pancreatitis
- Risk of acute pancreatitis, including fatal cases 5
- Stop medication immediately if severe abdominal pain occurs (may radiate to back, with or without vomiting)
Gallbladder Disease
- Increased risk of cholelithiasis and cholecystitis 5
- Weight loss from any modality increases gallstone risk; GLP-1 RAs appear to augment this 6
Acute Kidney Injury
- Usually associated with dehydration from GI side effects (nausea, vomiting, diarrhea) 1
- Emphasize maintaining hydration, especially during dose titration
Gastrointestinal Effects
- Nausea (40% with liraglutide vs 14.8% placebo) and vomiting (16% vs 4.3%) are common 5
- These are dose-dependent and typically improve with gradual titration 5
Practical Management Strategies
Minimizing GI Side Effects (Which Reduces Dehydration/Aspiration Risk)
Titration is critical 5:
- Semaglutide: Start 0.25 mg weekly × 4 weeks, then 0.5 mg × 4 weeks, then 1.0 mg × 4 weeks, then 1.7 mg × 4 weeks, reaching 2.4 mg at week 16
- Liraglutide: Start 0.6 mg daily × 7 days, then increase by 0.6 mg weekly until reaching 3.0 mg at week 4
- Tirzepatide: Start 2.5 mg weekly × 4 weeks, then increase by 2.5-5 mg every 4 weeks up to 15 mg 7
Dietary counseling 8:
- Avoid fatty foods that exacerbate nausea
- Eat smaller, more frequent meals
- Don't eat past the point of fullness
- Stay well-hydrated
Special Populations Requiring Extra Caution
Patients with cardiovascular disease planning surgery:
- Phentermine-topiramate should be avoided in those with CVD history 5
- GLP-1 RAs have cardiovascular benefits but the aspiration risk during surgery requires careful coordination with surgical teams
Patients on insulin or sulfonylureas:
- Increased hypoglycemia risk when combined with GLP-1 RAs 5
- Dose adjustments of insulin/sulfonylureas typically needed
Women of childbearing potential:
Documentation and Communication
In your patient's chart, document:
- That you counseled about aspiration risk with anesthesia
- That patient understands to inform all proceduralists about GLP-1 RA use
- That patient knows to report planned surgeries/procedures to you for medication management
Provide written instructions that patients can show to their surgical/procedural teams, including:
- Medication name and dose
- Frequency (daily vs weekly)
- Last dose taken
- Your contact information for coordination
The Bottom Line for Clinical Practice
The aspiration warning doesn't change the favorable benefit-risk profile of GLP-1 RAs for obesity management 5, but it requires proactive communication. The key is ensuring patients understand they must disclose GLP-1 RA use to any provider planning a procedure, and that you coordinate with surgical teams when your patients have planned procedures. The exact timing of medication cessation before procedures remains an area of active investigation, so individualized risk assessment with the anesthesia team is essential 2.